Ipca Laboratories Limited (IPCALAB)
ISIN: INE571A01038 Industry: Drug Manufacturers—Specialty & Generic Sector: Healthcare Website
868
-3.95(-0.45%)

Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.

Pricing Updates

TODAY'S HIGH

876.3

TODAY'S LOW

865

52 WEEK HIGH

1128.5

52 WEEK LOW

831.05

Major Holders

% of Shares Held by
All Insider

48.35%

% of Shares Held by
Institutions

40.48%

% of Float Held by
Institutions

78.36%

Number of Institutions
Holding Shares

92

Company Overview

MARKET CAP

22044.07 Cr.

ETERPRISE VALUE

21647.60 Cr.

NO. OF SHARES

25.37 Cr.

BOOK VALUE

227.667

DIV. YIELD

4%

DEBT

733.69 Cr.

GROSS PROFIT

3622.52 Cr.

CASH

1296.56 Cr.

REVENUE

5906.96 Cr.

REVENUE/SHARE

232.823

OHLC Chart 1y 2y 5y 10y

Price Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Volumes Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Cashflows

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Investments-235.76 Cr.-150.09 Cr.-166.05 Cr.-14.58 Cr.
Change To Liabilities-109.69 Cr.55.95 Cr.68.28 Cr.101.88 Cr.
Total cashflows from Investing Activities-855.05 Cr.-520.69 Cr.-509.65 Cr.-165.06 Cr.
Net Borrowings534.44 Cr.-231.69 Cr.-10.81 Cr.-174.60 Cr.
Total Cash from Financing Activities426.81 Cr.-305.82 Cr.-136.54 Cr.-183.20 Cr.
Other Liabilities166.33 Cr.-117.34 Cr.95.30 Cr.43.55 Cr.
Total Assets035.81 Cr.35.81 Cr.4.57 Cr.
Net Income884.08 Cr.1140.01 Cr.606.32 Cr.444.83 Cr.
Change in Cash431.92 Cr.263.62 Cr.-75.53 Cr.152.77 Cr.
Effect of Exchange Rate0000
Total Cash from Operating Activities856.04 Cr.1090.13 Cr.570.35 Cr.501.03 Cr.
Depreciation232.42 Cr.203.46 Cr.206.01 Cr.176.34 Cr.
Other Cashflows from Investing Activities-113.07 Cr.-11.62 Cr.58.75 Cr.28.19 Cr.
Dividends Paid-101.45 Cr.-101.53 Cr.-100.89 Cr.-12.81 Cr.
Change to Inventory-249.15 Cr.-271.69 Cr.-239.86 Cr.-191.91 Cr.
Change to Account Receivables-80.24 Cr.96.75 Cr.-187.41 Cr.-75.49 Cr.
Other Cashflows from Financing Activities-6.18 Cr.-8.41 Cr.-24.84 Cr.-36 Lakhs
Change to Net Income12.29 Cr.-22.72 Cr.17.22 Cr.-4.25 Cr.
Capital Expenditures-478.95 Cr.-361.55 Cr.-306.28 Cr.-180.54 Cr.

Financials

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Research DevelopmentNoneNoneNoneNone
Effect of Accounting ChargesNoneNoneNoneNone
Income Before Tax1114.56 Cr.1381.28 Cr.738.89 Cr.546.46 Cr.
Minority Interest76.92 Cr.14.53 Cr.13.63 Cr.15.54 Cr.
Net Income1076.84 Cr.1314.59 Cr.742.11 Cr.531.45 Cr.
Selling General Administrative1177.39 Cr.1030.89 Cr.936.17 Cr.810.29 Cr.
Gross Profit3814.94 Cr.3524.24 Cr.2862.13 Cr.2415.21 Cr.
Ebit1076.84 Cr.1314.59 Cr.742.11 Cr.531.45 Cr.
Operating Income1076.84 Cr.1314.59 Cr.742.11 Cr.531.45 Cr.
Other Operating Expenses1328.29 Cr.971.98 Cr.975.33 Cr.890 Cr.
Interest Expense-7.69 Cr.-8.61 Cr.-15.84 Cr.-18.30 Cr.
Extraordinary ItemsNoneNoneNoneNone
Non RecurringNoneNoneNoneNone
Other ItemsNoneNoneNoneNone
Income Tax Expense224.77 Cr.240.14 Cr.135.33 Cr.104.24 Cr.
Total Revenue5829.79 Cr.5420.73 Cr.4649.86 Cr.3774.96 Cr.
Total Operating Expenses4752.95 Cr.4106.14 Cr.3907.75 Cr.3243.51 Cr.
Cost of Revenue2014.85 Cr.1896.49 Cr.1787.73 Cr.1359.75 Cr.
Total Other Income Expense Net37.72 Cr.66.69 Cr.-3.22 Cr.15.01 Cr.
Discontinued OperationsNoneNoneNoneNone
Net Income from Continuous Ops.889.79 Cr.1141.14 Cr.603.56 Cr.442.22 Cr.
Net Income Applicable to Common Shares884.08 Cr.1140.01 Cr.606.32 Cr.444.83 Cr.

Balance Sheet

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Intangible Assets167.19 Cr.114.20 Cr.136.32 Cr.176.95 Cr.
Capital Surplus096.52 Cr.48.87 Cr.48.87 Cr.
Total Liabilities2069.97 Cr.1352.18 Cr.1618.72 Cr.1412.74 Cr.
Stock Holder Equity5491.97 Cr.4701.65 Cr.3627.48 Cr.3122.39 Cr.
Minority Interest76.92 Cr.14.53 Cr.13.63 Cr.15.54 Cr.
Other Liabilities507.64 Cr.196.43 Cr.288.38 Cr.227.11 Cr.
Total Assets7638.86 Cr.6068.36 Cr.5259.83 Cr.4550.67 Cr.
Common Stock25.37 Cr.25.37 Cr.25.27 Cr.25.27 Cr.
Retained Earnings04558.80 Cr.3519.43 Cr.3042.27 Cr.
Other Liabilities197.41 Cr.174.26 Cr.176.31 Cr.174.39 Cr.
Good Will54.16 Cr.46.60 Cr.62.44 Cr.47.20 Cr.
Treasury Stock5466.60 Cr.20.96 Cr.33.91 Cr.5.98 Cr.
Other Assets187.86 Cr.212.72 Cr.140.80 Cr.136.16 Cr.
Cash640.66 Cr.165.97 Cr.58.46 Cr.281.18 Cr.
Current Liabilities1465.88 Cr.1133.13 Cr.1326.42 Cr.1097.50 Cr.
Long Term Asset Charges2.02 Cr.1.95 Cr.2.01 Cr.1.84 Cr.
Short Long Term Debt396.06 Cr.66.60 Cr.67.91 Cr.114.41 Cr.
Other Stockholder Equity5466.60 Cr.20.96 Cr.33.91 Cr.5.98 Cr.
Property Plant Equipment2502.60 Cr.2146.45 Cr.1993.25 Cr.1782.56 Cr.
Total Cur. Assets4457.17 Cr.3436.96 Cr.2855.71 Cr.2377.75 Cr.
Long Term Investments269.88 Cr.111.43 Cr.71.31 Cr.30.05 Cr.
Net Tangible Assets5270.62 Cr.4540.85 Cr.3428.72 Cr.2898.24 Cr.
Short Term Investments719.31 Cr.197.84 Cr.121.15 Cr.0
Net Receivables921.12 Cr.1014 Cr.1074.59 Cr.873.35 Cr.
Long Term Debt395.18 Cr.36.54 Cr.102.97 Cr.140.85 Cr.
Inventory1857.97 Cr.1594.81 Cr.1323.12 Cr.1072.50 Cr.
Accounts Payable557.70 Cr.666.17 Cr.609.85 Cr.524.32 Cr.

New Offers


Upstox offer
Upstox

Open a demat account through us and get the account opening charges waived off

open paperless account